MWA Asset Management Purchases New Shares in Becton, Dickinson and Company $BDX

MWA Asset Management purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,197 shares of the medical instruments supplier’s stock, valued at approximately $786,000.

Other large investors have also made changes to their positions in the company. Bill Few Associates Inc. grew its position in shares of Becton, Dickinson and Company by 0.7% during the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 55 shares during the period. Gilbert & Cook Inc. grew its holdings in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after acquiring an additional 56 shares during the period. Mendel Money Management raised its position in shares of Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after acquiring an additional 58 shares during the last quarter. Focus Financial Network Inc. lifted its stake in shares of Becton, Dickinson and Company by 2.2% in the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after purchasing an additional 58 shares during the period. Finally, CX Institutional boosted its position in shares of Becton, Dickinson and Company by 3.6% in the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX opened at $203.56 on Friday. The business’s 50-day simple moving average is $198.54 and its 200 day simple moving average is $191.24. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm has a market capitalization of $58.00 billion, a PE ratio of 34.92, a PEG ratio of 2.22 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 17th. Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Bank of America raised their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $209.00.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,680 shares of company stock valued at $539,848. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.